SkGel implant provides stable IOP

Article

Deep sclerectomy with the SkGel implant (Corneal Laboratories) provides stable, long-term control of intraocular pressure (IOP) and visual field .

Deep sclerectomy with the SkGel implant (Corneal Laboratories) provides stable, long-term control of intraocular pressure (IOP) and visual field (VF), according to a report in the January/February issue of the Journal of Glaucoma.

Fernando Galassi and Barbara Giambene from the University of Florence, Florence, Italy evaluated the results of deep sclerectomy with the SkGel implant, a biodegradable cross-linked sodium hyaluronate drainage implant, at three and five years.

The retrospective trial included 200 eyes with open-angle glaucoma which had three years of follow-up and 97 eyes which had five years of follow-up. Mean IOP decreased from 21.01±5.56 mmHg prior to surgery to 13.13±2.24 mmHg at 36 months follow-up, and from 20.61±5.50 mmHg to 13.85±1.84 mmHg at 60 months follow-up (p<0.0005).

At three and five years, complete success rates (IOP ≤16 mmHg without medications) were 67.50% and 64.95%, partial success rates (IOP ≤16 mmHg with medications) were 21.50% and 24.74% and failure rates (IOP >16 mmHg) were 11% and 10.31%, respectively. Visual field testing revealed stable mean deviation and corrected pattern standard deviation values at three and five years (p>0.05).

This study demonstrates that deep sclerectomy with the SkGel implant results in stable long-term IOP and visual field.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.